Vaccines shown to induce lower levels of neutralising antibodies against Omicron coronavirus variant
On Dec. 13, 2021, researchers from the University of Oxford analysed the impact of the Omicron COVID-19 variant…
-
-
Pfizer and BioNTech received U.S. FDA EUA of COVID-19 vaccine booster for individuals 16 years and older
On Dec. 9, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
FDA authorized long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals
On Dec. 8, 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZenecaﾒs Evusheld…
-
CDC launched two global networks, awarded $22 million to combat antimicrobial resistance and infectious diseases
On Dec. 7, 2021, the Centers for Disease Control and Prevention announced that it had awarded $22 million…
-
Arbutus Biopharma, X-Chem and Proteros biostructures achieved first milestone under COVID-19 discovery research
On Dec. 7, 2021, Arbutus Biopharma, X-Chem, and Proteros announced that Arbutus had identified several molecules that inhibit…
-
CHMP recommended EU approval of Actemra/RoActemra to treat patients with severe COVID-19
On Dec. 6, 2021, Roche announced that the European Medicines Agencyﾒs Committee for Medicinal Products for Human Use…
-
WHO advised against use of convalescent plasma for covid-19
On Dec. 6, 2021, the World Health Organization Guideline Development Group of international experts announced in the BMJ…
-
USAID announced Initiative for Global Vaccine Access to accelerate vaccine access and delivery around the world
On Dec. 6, 2021, the USAID announced the foundation of a new whole-of-government effort, the Initiative for Global…
-
Johnson & Johnson COVID-19 booster showed substantial increase in antibody and T-cell responses
On Dec. 5, 2021, Johnson & Johnson announced preliminary results from an independent study, including a subset of…
-
Roche announced additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
On Dec. 3, 2021, Roche and TIB Molbiol announced they had added three additional Research Use Only test…
-
Gavi approved malaria vaccine programme funding
On Dec. 3, 2021, Gavi, the Vaccine Alliance, approved a new malaria vaccination programme to support the introduction,…
-
Genomics England sets out vision for newborn genomes research pilot
On Dec. 3, 2021, Genomics England has announced its vision for a pilot research project to examine the…
-
NIH scientists discovered new B cell that tempers autoimmunity
On Dec. 2, 2021, researchers at the National Eye Institute (NEI) announced they had identified, isolated, and characterized…
-
Resilience and Harvard University announced five-year R&D alliance to incubate new technologies
On Dec. 2, 2021, National Resilience and Harvard University announed they had established a five-year research and development…
-
Fulgent Genetics confirmed ability to detect Omicron variant with RT-PCR tests for COVID-19
On Dec. 1, 2021, Fulgent Genetics confirmed that the Companyﾒs RT-PCR test for SARS-CoV-2, the virus that causes…
-
Labcorp announced collection for COVID-19 PCR testing in over 500 Locations nationwide, with plans to double locations
On Nov. 30, 2021, LabCorp announced that it had begun offering observed self-collection for COVID-19 PCR testing in…
-
Thermo Fisher Scientific confirmed detection of SARS-CoV-2 in samples containing Omicron Variant with TaqPath COVID-19 tests
On Nov. 29, 2021, Thermo Fisher Scientific confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit…
-
WHO announced classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern
On Nov. 26, 2021, the World Health Organization announced that the Technical Advisory Group on SARS-CoV-2 Virus Evolution…
-
WHO and Medicines Patent Pool announced first transparent, global, non-exclusive licence for COVID-19 technology
On Nov. 23, 2021, the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized…
-
Oxitec successfully concluded mosquito releases in landmark Florida Keys pilot program
On Nov. 23, 2021, Oxitec announced the successful completion of the mosquito release phase of its landmark project…
-
Tonix Pharmaceuticals announced publication of paper on antiviral SARS-CoV-2 inhibitor, TNX-3500, in JCI Insight
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of ‘Sangivamycin is highly effective against SARS-CoV-2 in vitro…
-
Follow-up data from phase 3 trial of Pfizer-BioNTech COVID-19 vaccine supported safety and high efficacy in adolescents 12 through 15 years of age
On Nov. 22, 2021, Pfizer announced topline results from a longer-term analysis of the safety and efficacy of…
-
India completed national introduction of pneumococcal conjugate vaccine
On Nov. 21, 2021, Gavi, the Vaccine Alliance, announced that India has completed the national introduction of pneumococcal…
-
Pfizer and BioNTech received expanded U.S. FDA EUA of COVID-19 vaccine booster to include individuals 18 and older
On Nov. 19, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
Pfizer and MPP announced agreement for COVID-19 oral antiviral treatment candidate to expand access in low- and middle-income countries
On Nov. 16, 2021, Pfizer and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working…
-
Oxford / AstraZeneca vaccine reached two billion dose milestone
On Nov. 16, 2021, the University of Oxfordﾒs and AstraZeneca announced that two billion doses of the ChAdOx1…
-
Long-term study of children with COVID-19 began
On Nov. 15, 2021, a large, long-term study of the impacts of COVID-19 on children announced it had…
-
Oxford vaccine reached two billion dose milestone
On Nov. 15, 2021, AstraZeneca reported that 2 billion doses of the COVID-19 vaccine had been released for…
-
Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies
On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with…
-
Innovation Pharmaceuticals conducted full data analysis of phase 2 brilacidin COVID-19 trial results to support inclusion in Government-sponsored trials
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
